Yoichi Imai

Scopus Author ID ORCID

Publication Activity (10 Years)

Years Active: 2017-2024
Publications (10 Years): 14

Top Topics

Multiple Myeloma

Histone Deacetylase

Top Venues

Molecules and cells

International journal of hematology

Annals of hematology

This page only lists publications with an associated author ORCID identifier.

Publications

Yoichi Imai
Novel treatment strategies for hematological malignancies in the immunotherapy era. International journal of hematology (2024)
Yoichi Imai
Novel treatment strategies for hematological malignancies in the immunotherapy era. International journal of hematology 120 (1) (2024)
Mariko Ishibashi, Miwako Takahashi, Taiga Yamaya, Yoichi Imai
Current and Future PET Imaging for Multiple Myeloma. Life (Basel, Switzerland) 13 (8) (2023)
Masamitsu Mikami, Tatsuya Masuda, Takuya Kanatani, Mina Noura, Katsutsugu Umeda, Hidefumi Hiramatsu, Hirohito Kubota, Tomoo Daifu, Atsushi Iwai, Etsuko Yamamoto Hattori, Kana Furuichi, Saho Takasaki, Sunao Tanaka, Yasuzumi Matsui, Hidemasa Matsuo, Masahiro Hirata, Tatsuki R Kataoka, Tatsutoshi Nakahata, Yasumichi Kuwahara, Tomoko Iehara, Hajime Hosoi, Yoichi Imai, Junko Takita, Hiroshi Sugiyama, Souichi Adachi, Yasuhiko Kamikubo
RUNX1-Survivin Axis Is a Novel Therapeutic Target for Malignant Rhabdoid Tumors. Molecules and cells 45 (12) (2022)
Masamitsu Mikami, Tatsuya Masuda, Takuya Kanatani, Mina Noura, Katsutsugu Umeda, Hidefumi Hiramatsu, Hirohito Kubota, Tomoo Daifu, Atsushi Iwai, Etsuko Yamamoto Hattori, Kana Furuichi, Saho Takasaki, Sunao Tanaka, Yasuzumi Matsui, Hidemasa Matsuo, Masahiro Hirata, Tatsuki R Kataoka, Tatsutoshi Nakahata, Yasumichi Kuwahara, Tomoko Iehara, Hajime Hosoi, Yoichi Imai, Junko Takita, Hiroshi Sugiyama, Souichi Adachi, Yasuhiko Kamikubo
RUNX1-Survivin Axis Is a Novel Therapeutic Target for Malignant Rhabdoid Tumors. Molecules and cells 45 (12) (2022)
Masamitsu Mikami, Tatsuya Masuda, Takuya Kanatani, Mina Noura, Katsutsugu Umeda, Hidefumi Hiramatsu, Hirohito Kubota, Tomoo Daifu, Atsushi Iwai, Etsuko Yamamoto Hattori, Kana Furuichi, Saho Takasaki, Sunao Tanaka, Yasuzumi Matsui, Hidemasa Matsuo, Masahiro Hirata, Tatsuki R Kataoka, Tatsutoshi Nakahata, Yasumichi Kuwahara, Tomoko Iehara, Hajime Hosoi, Yoichi Imai, Junko Takita, Hiroshi Sugiyama, Souichi Adachi, Yasuhiko Kamikubo
RUNX1-Survivin Axis Is a Novel Therapeutic Target for Malignant Rhabdoid Tumors. Molecules and cells 45 (12) (2022)
Masamitsu Mikami, Tatsuya Masuda, Takuya Kanatani, Mina Noura, Katsutsugu Umeda, Hidefumi Hiramatsu, Hirohito Kubota, Tomoo Daifu, Atsushi Iwai, Etsuko Yamamoto Hattori, Kana Furuichi, Saho Takasaki, Sunao Tanaka, Yasuzumi Matsui, Hidemasa Matsuo, Masahiro Hirata, Tatsuki R Kataoka, Tatsutoshi Nakahata, Yasumichi Kuwahara, Tomoko Iehara, Hajime Hosoi, Yoichi Imai, Junko Takita, Hiroshi Sugiyama, Souichi Adachi, Yasuhiko Kamikubo
RUNX1-Survivin Axis Is a Novel Therapeutic Target for Malignant Rhabdoid Tumors. Molecules and cells 45 (12) (2022)
Hiroshi Yasui, Masayuki Kobayashi, Kota Sato, Kanya Kondoh, Tadao Ishida, Yuta Kaito, Hideto Tamura, Hiroshi Handa, Yutaka Tsukune, Makoto Sasaki, Norio Komatsu, Norina Tanaka, Junji Tanaka, Masahiro Kizaki, Toyotaka Kawamata, Junya Makiyama, Kazuaki Yokoyama, Seiya Imoto, Arinobu Tojo, Yoichi Imai
Circulating cell-free DNA in the peripheral blood plasma of patients is an informative biomarker for multiple myeloma relapse. International journal of clinical oncology 26 (11) (2021)
Tatsuya Masuda, Shintaro Maeda, Sae Shimada, Naoya Sakuramoto, Ken Morita, Asami Koyama, Kensho Suzuki, Yoshihide Mitsuda, Hidemasa Matsuo, Hirohito Kubota, Itaru Kato, Kuniaki Tanaka, Junko Takita, Masahiro Hirata, Tatsuki R Kataoka, Tatsutoshi Nakahata, Souichi Adachi, Hideyo Hirai, Shuichi Mizuta, Kazuhito Naka, Yoichi Imai, Shinya Kimura, Hiroshi Sugiyama, Yasuhiko Kamikubo
RUNX1 transactivates BCR-ABL1 expression in Philadelphia chromosome positive acute lymphoblastic leukemia. Cancer science 113 (2) (2021)
Jaeyong Cho, Yukio Horikawa, Mayumi Enya, Jun Takeda, Yoichi Imai, Yumi Imai, Hiroshi Handa, Takeshi Imai
L-Arginine prevents cereblon-mediated ubiquitination of glucokinase and stimulates glucose-6-phosphate production in pancreatic β-cells. Communications biology 3 (1) (2020)
Norina Tanaka, Yoichi Imai, Kentaro Yoshinaga, Masayuki Shiseki, Junji Tanaka
Fractionated ifosfamide, carboplatin, and etoposide with rituximab as a safe and effective treatment for relapsed/refractory diffuse large B cell lymphoma with severe comorbidities. Annals of hematology 99 (11) (2020)
Yoichi Imai
Latest Development in Multiple Myeloma. Cancers 12 (9) (2020)
Yoichi Imai, Mitsuhito Hirano, Masayuki Kobayashi, Muneyoshi Futami, Arinobu Tojo
HDAC Inhibitors Exert Anti-Myeloma Effects through Multiple Modes of Action. Cancers 11 (4) (2019)
Miho Ogawa, Kazuaki Yokoyama, Mitsuhito Hirano, Koji Jimbo, Kiyosumi Ochi, Toyotaka Kawamata, Nobuhiro Ohno, Eigo Shimizu, Nozomi Yokoyama, Rui Yamaguchi, Seiya Imoto, Kaoru Uchimaru, Naoto Takahashi, Satoru Miyano, Yoichi Imai, Arinobu Tojo
Different clonal dynamics of chronic myeloid leukaemia between bone marrow and the central nervous system. British journal of haematology 183 (5) (2017)